Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BHVNBullishCorporate Developmentsnews

High materiality8/10

Biohaven advances BHV-1300 in Graves' disease with expanding Phase 3 sites

Nov 5, 2026, 7:50 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Near-term catalysts (trial progress, Asia collaboration) could lift valuation; but outcomes remain trial-dependent with execution risk.

AI summary

What happened, with direct paths to the underlying reporting

Biohaven reported ATA posters highlighting Graves' disease program, patient experience, and MoDE/TRAP platforms. Phase 3 BHV-1300 enrollment is at 55+ U.S./Canada sites with Asia expansion tied to Ono's license for up to $80M upfront and milestones. Phase 1b showed ~80% TSHR-IgG1 reduction by week 12 and rapid normalization of thyroid hormones, underscoring potential if pivotal results are positive.

BHVN presents three ATA posters on Graves' disease, patient experience, and MoDE/TRAP platforms.
Phase 3 BHV-1300 enrollment at 55+ sites in US/Canada; expansion to Asia.
Phase 1b: ~80% TSHR-IgG1 reduction by week 12; rapid T4/T3 normalization.
Ono licenses MoDE portfolio in Asia for $80M upfront; milestone potential.
Graves' disease ~1% prevalence; no therapy approved in 70+ years.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Biohaven advances BHV-1300 in Graves' disease with expanding Phase 3 sites

Biohaven advances Vyglxia SCA filing; advisory input likely in 2027

Biohaven-Ono Asia license: $80M upfront, 20% royalties, non-dilutive cash

Biohaven Faces FDA Partial Clinical Hold on Epilepsy Program; Shares Fall

Biohaven secures SK licensing deal and Yale IP victory, boosting upside